CD8型
雄激素受体
流式细胞术
细胞毒性T细胞
生物
T细胞受体
T细胞
癌症研究
内分泌学
细胞生物学
癌症
免疫学
免疫系统
前列腺癌
体外
遗传学
作者
Tong Xiao,Johanna M. Schafer,No‐Joon Song,Cankun Wang,Payton Weltge,Xue Li,Qin Ma,Zihai Li
出处
期刊:Journal of Immunology
[American Association of Immunologists]
日期:2023-05-01
卷期号:210 (Supplement_1): 171.13-171.13
被引量:2
标识
DOI:10.4049/jimmunol.210.supp.171.13
摘要
Abstract Sex bias in cancers arising from nonreproductive organs is known but poorly understood. We recently reported on a T cell-intrinsic role of androgen receptor (AR) in driving CD8+ T cell exhaustion which underlies the poorer tumor control in males (Kwon et al., Sci Immunol, 2022). This study aims to understand how AR regulates CD8+ tumor-infiltrating lymphocytes (TILs) by identifying its genome-wide targets. We created a CD8+ T cell-specific AR knockout (KO) mouse model by crossing E8I-cre mice with Ar-floxed mice, which we challenged with syngeneic bladder tumor MB49. We then monitored tumor growth and performed spectral flow cytometry using a T cell exhaustion panel. Further, we used Cleavage Under Targets and Tagmentation – sequencing (CUT&Tag-seq) to map the entire AR targets in CD8+ TILs. Loss of AR in CD8+ T cells significantly slowed the growth of MB49 in male but not female mice. CD8+ TILs from male CD8 AR KO mice showed reduced TOX+ TCF1− terminally exhausted subset (69%; P≤ 0.05) and TOX expression (72%; P = 0.0583) compared to controls. Similarly, TOX expression decreased by 43% in AR-deleted CD8+ T cells following chronic TCR stimulation in vitro (P ≤ 0.0001). Finally, using CUT&Tag-seq, we found that AR binds directly to promoters of multiple key transcriptional regulators of T cell exhaustion, including Tcf7 and Tox. Through identifying the genome-wide targets of AR in CD8+ TILs, we characterized the cell-intrinsic mechanism by which AR regulates CD8+ T cell exhaustion. Our work suggests AR is a master transcriptional regulator that negatively impacts CD8+ T cell immunity, which may contribute to poorer survival in males and supports combining androgen deprivation therapy with immune checkpoint blockage for cancer treatment. Special Institutional Funding
科研通智能强力驱动
Strongly Powered by AbleSci AI